Literature DB >> 18561586

Prevalence and severity of facial and truncal acne in a referral cohort.

Jerry K L Tan1, Jing Tang, Karen Fung, Aditya K Gupta, D Richard Thomas, Sheetal Sapra, Charles Lynde, Yves Poulin, Wayne Gulliver, Rolf J Sebaldt.   

Abstract

BACKGROUND: There is a paucity of information on the prevalence and severity of acne of the face, chest, and back.
PURPOSE: This study was designed to examine the prevalence and severity of acne on the face, chest, and back in a referral cohort of patients with acne using a validated global acne severity scale.
METHODS: Acne patients referred to dermatologists were evaluated at the face, chest, and back. Chi-square testing was performed to assess consistency between patient and physician assessments of each region. The correlation of acne severity between regions was evaluated by Spearman's rank correlation.
RESULTS: In 965 patients, the prevalence of acne on the face, chest, and back was 92%, 45%, and 61%, respectively. Acne severity was significantly correlated for all regional pairs (P<.001): face and back (r=0.11); face and chest (r=0.12); and chest and back (r=0.67). The consistency of patient reporting and clinical evaluation for the presence of acne varied by region: face=92%, chest=69%, and back=74%. The proportions of patients reporting no occurrence of acne when clinical acne was indeed absent (negative predictive value) were 67% and 65% for the chest and back, respectively. LIMITATIONS: The operational threshold for clinical acne (>mild) may underestimate the total proportion of affected patients. These patients were referred to dermatologists for care and may represent a more severe cohort.
CONCLUSION: Acne affected the face in 92% and the trunk in just over 60% (with the back more frequently and severely affected than the chest). Acne severity was observed to have a much higher correlation between chest and back than face and back or face and chest. Patient-reporting evaluations of absence of acne on the chest and back are frequently erroneous, mandating clinical evaluations of these sites for assessment of overall extent.

Entities:  

Mesh:

Year:  2008        PMID: 18561586

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  6 in total

1.  Management of Truncal Acne Vulgaris with Topical Dapsone 7.5% Gel.

Authors:  James Q Del Rosso; Leon Kircik; Emil Tanghetti
Journal:  J Clin Aesthet Dermatol       Date:  2018-08-01

2.  A review of the safety and efficacy of benzoyl peroxide (5.3%) emollient foam in the management of truncal acne vulgaris.

Authors:  Joseph Bikowski
Journal:  J Clin Aesthet Dermatol       Date:  2010-11

3.  Subject Satisfaction with Trifarotene 50 μg/g Cream in the Treatment of Facial and Truncal Acne Vulgaris: A Case Series.

Authors:  Sandra M Johnson; Rajeev Chavda; Janet C DuBois
Journal:  Dermatol Ther (Heidelb)       Date:  2020-07-04

4.  Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne.

Authors:  U Blume-Peytavi; J Fowler; L Kemény; Z Draelos; F Cook-Bolden; T Dirschka; L Eichenfield; M Graeber; F Ahmad; A Alió Saenz; P Rich; E Tanghetti
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-08-20       Impact factor: 6.166

5.  Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panel.

Authors:  Jerry Tan; Andrew Alexis; Hilary Baldwin; Stefan Beissert; Vincenzo Bettoli; James Del Rosso; Brigitte Dréno; Linda Stein Gold; Julie Harper; Charles Lynde; Diane Thiboutot; Jonathan Weiss; Alison M Layton
Journal:  JAAD Int       Date:  2021-08-17

6.  The Personalised Acne Care Pathway-Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts.

Authors:  Jerry Tan; Andrew Alexis; Hilary Baldwin; Stefan Beissert; Vincenzo Bettoli; James Del Rosso; Brigitte Dréno; Linda Stein Gold; Julie Harper; Charles Lynde; Diane Thiboutot; Jonathan Weiss; Alison M Layton
Journal:  JAAD Int       Date:  2021-10-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.